Text: H.R.5582 — 115th Congress (2017-2018)All Information (Except Text)

Text available as:

Shown Here:
Referred in Senate (06/13/2018)

 
[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5582 Referred in Senate (RFS)]

<DOC>
115th CONGRESS
  2d Session
                                H. R. 5582


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             June 13, 2018

     Received; read twice and referred to the Committee on Finance

_______________________________________________________________________

                                 AN ACT


 
To direct the Secretary of Health and Human Services to conduct a study 
  and submit a report on barriers to accessing abuse-deterrent opioid 
 formulations for individuals enrolled in a plan under part C or D of 
                         the Medicare program.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited at the ``Abuse Deterrent Access Act of 
2018''.

SEC. 2. STUDY ON ABUSE-DETERRENT OPIOID FORMULATIONS ACCESS BARRIERS 
              UNDER MEDICARE.

    (a) In General.--Not later than on1e year after the date of the 
enactment of this Act, the Secretary of Health and Human Services shall 
conduct a study and submit to Congress a report on the adequacy of 
access to abuse-deterrent opioid formulations for individuals with 
chronic pain enrolled in an MA-PD plan under part C of title XVIII of 
the Social Security Act or a prescription drug plan under part D of 
such title of such Act, taking into account any barriers preventing 
such individuals from accessing such formulations under such MA-PD or 
part D plans, such as cost-sharing tiers, fail-first requirements, the 
price of such formulations, and prior authorization requirements.
    (b) Definition of Abuse-Deterrent Opioid Formulation.--In this 
section, the term ``abuse-deterrent opioid formulation'' means an 
opioid that is a prodrug or that has certain abuse-deterrent 
properties, such as physical or chemical barriers, agonist or 
antagonist combinations, aversion properties, delivery system 
mechanisms, or other features designed to prevent abuse of such opioid.

            Passed the House of Representatives June 12, 2018.

            Attest:

                                                 KAREN L. HAAS,

                                                                 Clerk.

Share This